Jin Feng, Zhu Hui, Fu Zheng, Kong Li, Yu Jinming
School of Medicine and Life Sciences, University of Jinan-Shandong Academy of Medical Sciences, Jinan, People's Republic of China; Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, People's Republic of China.
Onco Targets Ther. 2016 May 19;9:2993-9. doi: 10.2147/OTT.S104919. eCollection 2016.
The purpose of this study was to investigate the prognostic value of the standardized uptake value maximum (SUVmax) change calculated by dual-time-point (18)F-fluorodeoxyglucose positron emission tomography (PET) imaging in patients with advanced non-small-cell lung cancer (NSCLC).
We conducted a retrospective review of 115 patients with advanced NSCLC who underwent pretreatment dual-time-point (18)F-fluorodeoxyglucose PET acquired at 1 and 2 hours after injection. The SUVmax from early images (SUVmax1) and SUVmax from delayed images (SUVmax2) were recorded and used to calculate the SUVmax changes, including the SUVmax increment (ΔSUVmax) and percent change of the SUVmax (%ΔSUVmax). Progression-free survival (PFS) and overall survival (OS) were determined by the Kaplan-Meier method and were compared with the studied PET parameters, and the clinicopathological prognostic factors in univariate analyses and multivariate analyses were constructed using Cox proportional hazards regression.
One hundred and fifteen consecutive patients were reviewed, and the median follow-up time was 12.5 months. The estimated median PFS and OS were 3.8 and 9.6 months, respectively. In univariate analysis, SUVmax1, SUVmax2, ΔSUVmax, %ΔSUVmax, clinical stage, and Eastern Cooperative Oncology Group (ECOG) scores were significant prognostic factors for PFS. Similar results were significantly correlated with OS, except %ΔSUVmax. In multivariate analysis, ΔSUVmax and %ΔSUVmax were significant factors for PFS. On the other hand, ECOG scores were only identified as independent predictors of OS.
Our results demonstrated the prognostic value of the SUVmax change in predicting the PFS of patients with advanced NSCLC. However, SUVmax change could not predict OS.
本研究旨在探讨双时相（18）F - 氟脱氧葡萄糖正电子发射断层扫描（PET）成像计算的标准化摄取值最大值（SUVmax）变化在晚期非小细胞肺癌（NSCLC）患者中的预后价值。
我们对115例晚期NSCLC患者进行了回顾性研究，这些患者在注射后1小时和2小时接受了预处理双时相（18）F - 氟脱氧葡萄糖PET检查。记录早期图像的SUVmax（SUVmax1）和延迟图像的SUVmax（SUVmax2），并用于计算SUVmax变化，包括SUVmax增量（ΔSUVmax）和SUVmax百分比变化（%ΔSUVmax）。无进展生存期（PFS）和总生存期（OS）采用Kaplan - Meier法确定，并与研究的PET参数进行比较，单因素分析和多因素分析中的临床病理预后因素使用Cox比例风险回归构建。
共回顾了115例连续患者，中位随访时间为12.5个月。估计的中位PFS和OS分别为3.8个月和9.6个月。在单因素分析中，SUVmax1、SUVmax2、ΔSUVmax、%ΔSUVmax、临床分期和东部肿瘤协作组（ECOG）评分是PFS的显著预后因素。除%ΔSUVmax外，类似结果与OS显著相关。在多因素分析中，ΔSUVmax和%ΔSUVmax是PFS的显著因素。另一方面，ECOG评分仅被确定为OS的独立预测因素。
我们的结果证明了SUVmax变化在预测晚期NSCLC患者PFS方面的预后价值。然而，SUVmax变化不能预测OS。
